Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

Between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes. For several years, GLP1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss. Because of the insulin-sensitizing power of GLP1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control. The investigators propose to use in this study semaglutide, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).

NCT Number	NCT05305794
Lead Sponsor	Centre Hospitalier Universitaire Dijon
Conditions	Double Diabetes
Enrollment	76 participants
Start Date	2022-07-12
Primary Completion	2028-08 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-18